Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat

1 month ago 16

Maham Fatima

Wed, February 4, 2026 astatine 8:05 AM CST 1 min read

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 1 of the inexpensive blistery stocks to put successful close now. On January 30, Barclays expert Glen Santangelo raised the terms people for Teva Pharmaceuticals to $38 from $35 with an Overweight rating. Following Teva Pharmaceuticals’ Q4 2025 report, the steadfast updated its fiscal exemplary and expressed continued assurance successful the stock’s existent valuation.

A time earlier that, Scotiabank raised the terms people connected Teva Pharmaceuticals to $40 from $35 portion maintaining an Outperform rating. The steadfast is affirmative connected the banal pursuing Q4 2025 results and noted that the company’s execution continues to transcend expectations.

In different news, connected January 14, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced that the New England Journal of Medicine published Phase 3 information from the SPACE trial, confirming that AJOVY (fremanezumab-vfrm) importantly reduces monthly migraine and headache days successful children and adolescents (ages 6–17). Following its August 2025 FDA support for pediatric patients weighing 45 kg oregon more, AJOVY is present the archetypal and lone CGRP antagonist disposable for some adults and children.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic and different medicines & biopharmaceutical products successful the US, Europe, Israel, and internationally.

While we admit the imaginable of TEVA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.